An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study

To evaluate the efficacy and safety of apatinib, an oral antiangiogenic drug, in patients with recurrent or refractory cervical cancer as salvage treatment, we retrospectively analyzed the medical records of recurrent or refractory cervical cancer patients admitted to the National Cancer Center/Canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Wang, Ziyi, Yuan, Guangwen, Sun, Yangchun, Zhang, Rong, Li, Xiaoguang, Li, Nan, Wang, Jing, Wu, Lingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327550/
https://www.ncbi.nlm.nih.gov/pubmed/32655637
http://dx.doi.org/10.1155/2020/3852373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327550/
https://www.ncbi.nlm.nih.gov/pubmed/32655637
http://dx.doi.org/10.1155/2020/3852373

Ejemplares similares